Phuturdex › Drugs › Pamvatamig
Drugs in development · updated 11 November 2026
Pamvatamig: clinical trials and development status
Other names and codes: MCLA-129
As of 11 November 2026 Pamvatamig is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 3 diseases. The most advanced phase is II.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A human bispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, pamvatamig simultaneously targets and binds to the extracellular domains of both EGFR and c-Met expressed on cancer cells. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways. The binding results in antibody-dependent cellular cytotoxicity (ADCC), thereby inhibiting tumor cell proliferation and survival. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Non-small-cell lung carcinoma | II | 2 | NCT06885840 |
| Colorectal neoplasm | I–II | 1 | NCT04930432 |
| Head and neck neoplasms | I–II | 1 | NCT04930432 |
Everything on Pamvatamig
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.